CDR2 and metastatic neoplasm: Establishing the diagnosis involves ruling out metastatic disease, treatment toxicity, infection, and metabolic disturbances, and often hinges on finding antineuronal antibodies (most commonly anti-Yo, also called type-1 anti-Purkinje cell antibody or PCA-1) in blood or cerebrospinal fluid (CSF).